Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Mattig

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
European Heart Journal. Case Reports|March 19, 2021
Progression of electrocardiogram changes in an untreated fabry disease: a case reportIsabel Mattig, Sima Canaan-Kühl, Christoph Tillmanns, et al.
International Journal of Cardiology|November 26, 2021
Incidence of lead erosion in a real-world cohort and a case of successful treatment with an antimicrobial meshIsabel Mattig, Henryk Dreger, Sebastian Spencker, et al.
Scientific Reports|November 9, 2021
Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantationBernd Hewing, Isabel Mattig, Fabian Knebel, et al.
Echocardiography (Mount Kisco, N.Y.)|June 15, 2020
Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart functionIsabel Mattig, Fabian Knebel, Bernd Hewing, et al.
Scientific Reports|August 28, 2024
Predictors of residual tricuspid regurgitation after interventional therapy: an automated deep-learning CT analysisIsabel Mattig, Elena Romero Dorta, Katherine Fitch, et al.
Cardiovascular Ultrasound|September 26, 2023
Prevalence, one-year-incidence and predictors of carcinoid heart diseaseIsabel Mattig, Maximilian Richard Franke, Rene Pschowski, et al.
American Heart Journal Plus : Cardiology Research and Practice|May 25, 2026
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational studyIsabel Mattig, Berit Zirkelbach, Carina Bonnekoh, et al.
JACC. Advances|January 18, 2025
Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis EraMaximilian Leo Müller, Sebastian Spethmann, Daniel Messroghli, et al.
Echocardiography (Mount Kisco, N.Y.)|October 21, 2021
Comparative analysis of phasic left atrial strain and left ventricular posterolateral strain pattern to discriminate Fabry cardiomyopathy from other forms of left ventricular hypertrophyDavid Frumkin, Isabel Mattig, Nina Laule, et al.
Journal of the American Heart Association|July 3, 2024
Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World DataMaximilian Leo Müller, Ekaterina Latinova, Anna Brand, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
European Heart Journal. Case Reports|March 19, 2021
Progression of electrocardiogram changes in an untreated fabry disease: a case reportIsabel Mattig, Sima Canaan-Kühl, Christoph Tillmanns, et al.
International Journal of Cardiology|November 26, 2021
Incidence of lead erosion in a real-world cohort and a case of successful treatment with an antimicrobial meshIsabel Mattig, Henryk Dreger, Sebastian Spencker, et al.
Scientific Reports|November 9, 2021
Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantationBernd Hewing, Isabel Mattig, Fabian Knebel, et al.
Echocardiography (Mount Kisco, N.Y.)|June 15, 2020
Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart functionIsabel Mattig, Fabian Knebel, Bernd Hewing, et al.
Scientific Reports|August 28, 2024
Predictors of residual tricuspid regurgitation after interventional therapy: an automated deep-learning CT analysisIsabel Mattig, Elena Romero Dorta, Katherine Fitch, et al.
Cardiovascular Ultrasound|September 26, 2023
Prevalence, one-year-incidence and predictors of carcinoid heart diseaseIsabel Mattig, Maximilian Richard Franke, Rene Pschowski, et al.
American Heart Journal Plus : Cardiology Research and Practice|May 25, 2026
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational studyIsabel Mattig, Berit Zirkelbach, Carina Bonnekoh, et al.
JACC. Advances|January 18, 2025
Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis EraMaximilian Leo Müller, Sebastian Spethmann, Daniel Messroghli, et al.
Echocardiography (Mount Kisco, N.Y.)|October 21, 2021
Comparative analysis of phasic left atrial strain and left ventricular posterolateral strain pattern to discriminate Fabry cardiomyopathy from other forms of left ventricular hypertrophyDavid Frumkin, Isabel Mattig, Nina Laule, et al.
Journal of the American Heart Association|July 3, 2024
Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World DataMaximilian Leo Müller, Ekaterina Latinova, Anna Brand, et al.
Pageof 4